WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ
REGIONAL OFFICE FOR EUROPE BUREAU RÉGIONAL DE L'EUROPE
WELTGESUNDHEITSORGANISATION ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
REGIONALBÜRO FÜR EUROPA ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО
Regional workshop on advancing /2
implementation science on HIV and viral
hepatitis in eastern Europe and Central Asia
Berlin, Germany 15 November 2019
10-11 February 2020 Original: English
Scope and purpose
Background
The WHO Region for Europe has an estimated 2.5 million people living with HIV, including 1.7 million
in eastern Europe and central Asia (EECA)1. Each year new HIV diagnoses continue to rise. In 2017,
there were about 160 000 new HIV diagnoses of whom more than 80% originated from EECA2. Despite
evidence that key populations are major drivers of the epidemic in most countries, comprehensive
preventive measures, including harm reduction programmes for people who inject drugs and combination
prevention programmes for men who have sex with men and other key and bridging populations are
inadequate. In addition, there is a need to scale up implementation of the latest WHO recommendations
and address services delivery barriers throughout the continuum of care, from testing to treatment in
order to improve the persistent gap toward the 90-90-90 cascade targets (which stood at 82%-66%-84%
for the Region and 72%-54%-77% in EECA as of 2018).
The Region is also home to an estimated 14 million people with chronic hepatitis C (HCV). It is
estimated that 31% of those who are infected with HCV are diagnosed and only 5% of those diagnosed
started on treatment. About 15 million people are estimated to have chronic hepatitis B among whom
only 13% are diagnosed. Countries of the Region have developed national action plans to address viral
hepatitis and strategies and service delivery models to diagnose and treat people with chronic hepatitis
are being developed. Vulnerable groups often have overlapping HIV-hepatitis and TB risks and co-
morbidities to be addressed in an integrated manner. Inadequate
At this juncture of the HIV and hepatitis response, there is an increasing need for generating and using
scientific and programmatic evidence on how to optimize the practical implementation of evidence-based
policies and recommendations in diverse real-world social, cultural, economic and health-system settings.
Investigating and addressing barriers that limit program quality, efficiency and effectiveness, or testing
and determining which alternative service delivery strategy would yield most impact, are central themes
of implementation science and key to elimination.
Against this background, a regional workshop on “advancing implementation science on HIV and viral
hepatitis in the WHO European region” will be held on 10-11 February 2020 in Berlin, Germany.
Overall purpose of the event
1
UNAIDS. AIDSinfo database (https://aidsinfo.unaids.org/).
2
ECDC/WHO. HIV/AIDS Surveillance in Europe 2018 – 2017 data. Copenhagen: WHO Regional Office for Europe; 2018.
Scope and purpose
page 2
The workshop aims at supporting the participants in conducting and using implementation science and
programme data to guide the practical implementation of WHO recommendations within their HIV, viral
hepatitis and integrated TB/HIV/viral Hepatitis programmes. It also aims at fostering collaboration
between academics, scientists, funders and partners to conduct and support implementation science.
Objectives
1. To share relevant examples of HIV, viral hepatitis and integrated TB/HIV/Viral Hepatitis
implementation science and how their findings have been used for decision making and programme
improvement;
2. To improve capacity to use programme data as well as generating and using scientific evidence from
HIV, hepatitis and TB/HIV/Viral Hepatitis implementation science to improve the efficiency of
national programmes;
3. To propose a draft HIV and Viral Hepatitis implementation research agenda for eastern Europe and
central Asia.
Expected results and outputs
• Overview of the extent to which implementation science is being conducted and used in the countries
of eastern Europe and central Asia.
• Agreed way forward and next steps for developing an implementation research agenda, including
options for strengthened collaboration between researchers across the Region.
• Meeting report prepared by the WHO Regional Office for Europe and published online.
Event Format
The workshop will be organized in collaboration with the Robert Koch Institute (RKI), and will be held
in Berlin, Germany on 10-11 February 2020.
The meeting is envisaged as a regional workshop with a mix of plenary sessions and working sessions on
defined topics.
In addition to WHO and its Collaborating Centre representatives, speakers will include researchers from
across the WHO European Region who have led relevant examples of implementation science and data
use leading to programme improvement.
Participants
The workshop will bring together EECA country representatives alongside academics, experts,
clinicians, communities, partners and donors from across the WHO European Region.
Specifically, participants will include:
• A team of three representatives from 15 countries3 which include two nominated country participants
(one person responsible for HIV surveillance and research and one HIV or hepatitis treatment expert
or national programme manager) as well as civil society representatives, preferably all with
experience in research.
• Representatives of academic institutions, WHO Collaborating Centres, researchers, invited experts
and speakers, partner agencies and donors.
• Representatives from WHO Regional Office for Europe, country offices and headquarters.
3
Armenia, Azerbaijan, Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Republic of Moldova, Russian
Federation, Tajikistan, Turkmenistan, Ukraine and Uzbekistan.
Saatja: EURO HIV <
[email protected]>
Saadetud: 18.11.2019 13:01
Adressaat: Elen Ohov <
[email protected]>
Koopia: SM Info <
[email protected]>; <
[email protected]>;
<
[email protected]>; REINAP, Marge <
[email protected]>; REINAP,
Marge <
[email protected]>; SEGUY, Nicole Simone <
[email protected]>;
STENGAARD, Annemarie <
[email protected]>; RUNDSTROEM, Maria
<
[email protected]>; ROMERO, Adriana Natalia <
[email protected]>
Teema: Regional workshop on advancing implementation science on HIV and
viral hepatitis in eastern Europe and central Asia Berlin, Germany, 10-11
February 2020
Dear Ms Ohov,
For your kind perusal, we are pleased to enclosed herewith request for
nomination letter concerning upcoming Regional workshop on advancing
implementation science on HIV and viral hepatitis in eastern Europe and
central Asia Berlin, Germany, 10-11 February 2020.
We would highly appreciate receiving nomination from your country by 18
December 2019 in order to arrange necessary logistic for the participants
on time.
With kind regards,
JTH Team
WORLD HEALTH ORGANIZATION
ORGANISATION MONDIALE DE LA SANTÉ
WELTGESUNDHEITSORGANISATION Date: 18 November 2019
ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
REGIONAL OFFICE FOR EUROPE Ms Elen Ohov
BUREAU RÉGIONAL DE L’EUROPE
REGIONALBÜRO FÜR EUROPA
Adviser
ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО European Union Affairs and International Co-
Head office:
operation Department
UN City, Marmorvej 51, Ministry of Social Affairs
DK-2100 Copenhagen Ø, Denmark Suur-Ameerika 1
Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01
Email:
[email protected] Tallinn 10122
Website: http://www.euro.who.int Estonia
Email:
[email protected]
Our reference: JTH Your reference:
Notre référence: ANB/ Votre référence:
Unser Zeichen: Ihr Zeichen:
См. наш номер: На Ваш номер:
Dear Ms Ohov,
Regional workshop on advancing implementation science on
HIV and viral hepatitis in eastern Europe and central Asia
Berlin, Germany, 10-11 February 2020
I have the honour to inform you that the World Health Organization Regional Office for Europe
(WHO/Europe) in collaboration with the Robert Koch Institute is convening the above-mentioned
workshop in Berlin, Germany on 10-11 February 2020.
Global strategies and regional and national action plans on the health sector response to HIV and
Viral Hepatitis are in place, however, there is an increasing need for generating and using scientific
and programmatic evidence on how to optimize the practical implementation of WHO
recommendations taking into account the social, cultural, economic and health-system settings.
The workshop aims at strengthening the use of implementation science and programme data to
improve the efficiency of national HIV and Viral Hepatitis programmes, fostering further
collaboration between national and international partners and researches and proposing a draft HIV
and Viral Hepatitis implementation research agenda for eastern Europe and central Asia (EECA).
The specific workshop objectives are described in the enclosed scope and purpose.
It is my pleasure to invite you to nominate two participants to attend this event:
• A technical expert with strong experience in HIV surveillance, analysis and research.
• A senior national staff with responsibility for the overall practical implementation of HIV
and/or Viral Hepatitis prevention, testing and treatment activities in your country, preferably
with experience in implementation research.
In addition, WHO/Europe will invite representatives from civil society to join the respective country
teams, aiming to facilitate strong collaboration between the government and civil sectors for defining
and strengthening an implementation research agenda and practical next steps.
UN City, Marmorvej 51 Tel.: +45 45 33 70 00 Email:
[email protected]
DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: http://www.euro.who.int
Denmark
The working language will be English and simultaneous Russian interpretation will be provided.
Travel and accommodation for participants will be arranged and paid for by this office in
accordance with our travel regulations.
I look forward to receiving your nominations, giving the names, functional titles and addresses of
the proposed participants at your earliest convenience and no later than Wednesday 18 December
2019. We shall then communicate with the nominees directly and provide the necessary
documentation and administrative information.
For further queries, please contact Dr Nicole Seguy, HIV/viral hepatitis Unit Lead
(
[email protected] with a copy to
[email protected]).
Yours sincerely,
Dr Masoud Dara
Coordinator, Communicable Diseases Department
Division of Health Emergencies and Communicable Diseases
WHO Regional Office for Europe
Enclosures:
Scope and Purpose
Copy for information:
Ms Triin Uusberg, Head, European and International Coordination Department, Ministry of Social Affairs, Suur-
Ameerika 1, Tallinn 10129, Estonia Email:
[email protected],
[email protected]
H.E. Ms Katrin Saarsalu-Layachi, Ambassador Extraordinary and Plenipotentiary, Permanent Representative,
Permanent Mission of the Republic of Estonia to the United Nations Office and other international organizations in
Geneva, Chemin du Petit-Saconnex 28A, Genève CH-1209, Switzerland Email:
[email protected]
H.E. Mr Märt Volmer, Ambassador Extraordinary and Plenipotentiary, Embassy of the Republic of Estonia,
Frederiksgade 19, 4th floor, Copenhagen K 1265, Denmark Email:
[email protected]
Ms Marge Reinap, Head of WHO Office, WHO Country Office, Estonia, Paldiski Road 81, Tallinn 10617, Estonia,
Email:
[email protected],
[email protected]
–2–